Drug Trial Radar · NCT07592910
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
May 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Prostate Cancer Clinical Trials ConsortiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.
Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Prostate Cancer (Adenocarcinoma)
Interventions
MevrometostatDrug
875 mg oral tablet, taken twice daily with food
EnzalutamideDrug
160 mg oral capsule, taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic progression free survival (rPFS)Time frame: From treatment initiation until documented disease progression, death, lost to follow-up, withdrawal, administrative censoring at the time of final analysis, whichever comes first, assessed up to 24 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.